Biotech firm Onxeo appoints Dr. Shefali Agarwal as President and CEO

Boston: Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), has announced the appointment of Dr. Shefali Agarwal as President and Chief Executive Officer. Dr. Agarwal succeeds Julien Miara, a Principal at Invus SAS, who was named interim CEO in January 2022.

“I have worked side by side with Dr. Agarwal in her capacity as Chairwoman to grow our Company, strengthen our Board and, importantly, advance our pipeline. It became very clear to me and the Board that Dr. Agarwal, who has extensive experience in drug development, was the right choice to fill the CEO role,” said Julien Miara, interim CEO. “She has the expertise to partner with our strong team on expeditiously progressing AsiDNA® through the clinic, developing our robust, pre-clinical pipeline and providing Onxeo with international visibility given her exposure among the U.S. investment community.”

Dr. Agarwal is a physician by training, and, until recently, was the Chief Medical and Development Officer at Epizyme, Inc., a biopharmaceutical company developing novel epigenetic therapies for cancer, where she led global clinical development and regulatory strategy. She will remain an advisor to Epizyme in a consultant role while fulfilling her duties at Onxeo.

Prior to joining Epizyme in 2018, Dr. Agarwal held various leadership positions across medical research, clinical development, clinical operations, and medical affairs. In addition to receiving her medical degree, Dr. Agarwal holds a Master of Public Health and a Master of Science in business.

Image courtesy of (Image provided)

Share this post